N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
Dermatosis Papulosa Nigra
Primary: Physician's DPN Lesions Assessment — -0.75; -1.38; -0.92 score on a scale (PLA)
Phase 3 N=50 Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Acne Vulgaris
Primary: Subject 's Overall Satisfaction With Study Treatment Via a Satisfaction Questionnaire — 36 Participants
Phase 4 N=20 Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color
Acne Vulgaris
Primary: Mean Change From Baseline to Week 12 in Global Acne Assessment Score (GAAS) — -0.86 score on a scale
Phase 4 N=68 A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in the Global Assessment of Acne Severity (GAAS) Score by Physician — 2.8; -1.2 score on a scale
N/A N=58 Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study
Lesion Skin · Seborrheic Keratosis
Primary: Clearance of SK Lesions — 82 percentage of SK lesion clearance
N/A N=72 Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
Skin Lesion · Skin Abnormalities · Sebaceous Hyperplasia
Primary: Total Number of Cleared SH Lesions — 99.5 Percentage of cleared SH Lesions
Phase 2 N=20 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Phase 4 N=100 Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color
Nasolabial Folds
Primary: Number Participants With Hypertropic Scarring, Keloid Formation, Hyper- or Hypopigmentation in Patients With Fitzpatrick Skin Types IV, V, and VI Receiving Nasolabial…
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
Phase 1 N=1 Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Neurofibromatoses
Primary: Part 1: Photosensitizer Uptake and Conversion to Protoporphyrin IX — 304 Densitometry units/micrometer squared — p=0.0001
Phase 4 N=10 A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008
N/A N=49 Visualizing Dermal Micropores With OCT
Healthy
Primary: Micropore Depth, Upper Arm — 72.4 micrometer
N/A N=11 Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy
Acne Keloidalis Nuchae
Primary: Percentage Change in Total AKN Lesions From Baseline to Week 16. — 49 percentage of lesion count reduction
Phase 1 N=31 DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone
Actinic Porokeratosis
Primary: Measurement of Treatment Efficacy Determined by DSAP-GASI Score (Disseminated Actinic Porokeratosis General Assessment Severity Index) — 50.0; 51.4 Percent decrease in…
Phase 4 N=30 Photodynamic Therapy for Papulopustular Rosacea
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
N/A N=30 Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
Pigmented Skin Lesion
Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations
N/A N=328 Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis
Lichen Sclerosus · Lichen Planus · Lichen Simplex Chronicus
Primary: Diagnostic Accuracy of "Three Rings Vulvoscopy" by the "Vulvoscopy Index" for Detection of Vulvar Dermatosis — 72; 0; 10; 246 Participants — p=0.6108
Phase 4 N=21 The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Investigator Global Assessment Scale for Severity of Facial Acne — 0; 0; 11; 9 Participants
N/A N=115 PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles
Benign Pigmented Lesions · Facial Wrinkles
Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale
N/A N=100 Safety Study of Cosmetic Tissue Augmentation in People of Color
Wrinkles
Primary: Keloid Formation at Site of Injection — 0.0 percentage of participants
N/A N=43 Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
Nevi
Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations
Phase 4 N=163 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts (Papules, Pustules and Nodules) at Week 12 — 38.96; 40.06; -24.05; -25.82 Number of Lesions
N/A N=23 Treatment of Keratosis Pilaris With 810 nm Diode Laser
Keratosis Pilaris (KP)
Primary: Difference in Disease Severity Scores — 4; 3 units on a scale
N/A N=24 Nanopulse Efficacy Study for the Treatment of Common Warts
Common Warts
Primary: Clinical Clearance of Warts — 13; 4; 2 # of warts
Phase 4 N=171 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12 — 38.94; 40.78; -25.77; -24.82 Number of Lesions
Phase 3 N=66 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Complete Response (CR) — 67; 18 percentage of participants — p=<0.001
Phase 2 N=20 Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
N/A N=13 Pilot Study of Laser Hair Depilation for Pilonidal Disease
Pilonidal Disease
Primary: Tolerability of Laser Treatment — 2 score on a scale